dostarlimab
gsk
['rectal']
in this phase 2 trial of 12 patients with stage 2-3 msi-h #rectalcancer, single agent anti-pd1 therapy was associated with a 100% ccr (6-25mo f/u) promising future of immunoablative therapy! via 
Dad & Husband • PGY-5 @UofTGSx, via @uoftmedicine @MacBHSc • MSc @UofTSLI @ihpmeuoft • Leadership, PROs & value-based cancer care.